During the last two decades front-line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) has profoundly changed moving from the old “one size fits all” concept to a “histology-based” approach and then, for a small subgroup of patients to a “molecularly-selected” one. The development of immune checkpoint inhibitors and the unprecedented results reported in 2nd/3rd line prompted the evaluation of these novel therapeutic agents in chemotherapy-naïve patients either alone or in combination with platinum-based chemotherapy. Several randomized trials are evaluating the impact of immune-checkpoint inhibitors in 1st line and some of them have yet produced preliminary evidence of efficacy. However, still a long way to go and several questions are still unanswered, including proper patients selection, optimal sequential/combinatorial use of these agents, appropriate treatment duration, and finally the identification of predictive biomarkers. The aim of this paper is to provide a comprehensive overview on the growing role of immune checkpoint inhibitors in the upfront treatment of advanced non-oncogene addicted NSCLC either as single agent or in combination with other agents.
Titolo: | The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy |
Autori: | RUSSO, ALESSANDRO (Primo) ADAMO, Vincenzo (Ultimo) (Corresponding) |
Data di pubblicazione: | 2018 |
Rivista: | |
Abstract: | During the last two decades front-line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) has profoundly changed moving from the old “one size fits all” concept to a “histology-based” approach and then, for a small subgroup of patients to a “molecularly-selected” one. The development of immune checkpoint inhibitors and the unprecedented results reported in 2nd/3rd line prompted the evaluation of these novel therapeutic agents in chemotherapy-naïve patients either alone or in combination with platinum-based chemotherapy. Several randomized trials are evaluating the impact of immune-checkpoint inhibitors in 1st line and some of them have yet produced preliminary evidence of efficacy. However, still a long way to go and several questions are still unanswered, including proper patients selection, optimal sequential/combinatorial use of these agents, appropriate treatment duration, and finally the identification of predictive biomarkers. The aim of this paper is to provide a comprehensive overview on the growing role of immune checkpoint inhibitors in the upfront treatment of advanced non-oncogene addicted NSCLC either as single agent or in combination with other agents. |
Handle: | http://hdl.handle.net/11570/3169092 |
Appare nelle tipologie: | 14.a.1 Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
Changing_scenario_2018.pdf | Versione Editoriale (PDF) | Tutti i diritti riservati (All rights reserved) | Utenti riconosciuti Richiedi una copia |